<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01509118</url>
  </required_header>
  <id_info>
    <org_study_id>15635</org_study_id>
    <nct_id>NCT01509118</nct_id>
  </id_info>
  <brief_title>Rivaroxaban Safety Profile in the Prophylaxis of Venous Thromboembolism After Hip Fracture Surgery</brief_title>
  <official_title>Rivaroxaban Safety Profile in the Prophylaxis of Venous Thromboembolism After Hip Fracture Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Phramongkutklao College of Medicine and Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chulalongkorn University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chiang Mai University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Thammasat University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Police General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Saint Louis Hospital,bangkok,Thailand</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bhumibol Adulyadej Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Phramongkutklao College of Medicine and Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Arterial and venous thromboembolism represents one of the most common preventable health
      problems. Patients undergoing surgery, especially hip fracture surgery are at high risk for
      deep vein thromboembolism (VTE) without thromboprophylaxis. In the absence of prophylaxis,
      the incidence of fatal pulmonary embolism (PE) after Hip Fracture Surgery (HFS) is reportedly
      4%-12%. Provision of thromboprophylaxis to all patients who undergo HFS is recommended.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rivaroxaban is the first agent of a new class of drugs acting as direct factor Xa inhibitors
      with oral bioavailability. Highly selective inhibition of factor Xa by rivaroxaban is
      expected to inhibit the amplified burst of thrombin generation and may result in more
      effective inhibition of thrombus formation with a favorable safety profile. In Thailand
      rivaroxaban is indicated for the prevention of VTE in patients undergoing major orthopedic
      surgery of the lower limbs including surgery for hip fractures. There are limited number of
      observational studies of rivaroxaban in thromboembolism after hip fracture surgery as the
      approved indication in most countries are for thromboprophylaxis in hip and knee
      arthroplasty. The broader indications and the high number of hip fracture surgeries in
      Thailand allow us to explore a pattern of safety profile particularly bleeding complications
      and risk factors in patients receiving rivaroxaban thromboprophylaxis after hip fracture
      surgery.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2011</start_date>
  <completion_date type="Anticipated">September 2013</completion_date>
  <primary_completion_date type="Anticipated">June 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Open Fracture of Hip</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Rivaroxaban safety profile will be observed in 500 patients
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 50 years old in men or post-menopause in women

          -  Patients, who are undergoing standard surgery for fracture of the upper third of the
             femur, including femoral head, neck, trochanteric and sub-trochanteric fracture and
             the surgery is planned within 7 days after admission

          -  Patients, who are eligible for thromboprophylaxis. Such patients will be enrolled only
             after physician's decision to prescribe rivaroxaban for thromboprophylaxis has been
             made. The decision is totally based on standard of medical practice.

          -  Patients, who agree to participate, return to follow-up visits, and who have signed
             informed consent to participate in the study.

        Exclusion Criteria:

          -  Trauma affecting more than 1 organ system

          -  Pathological fracture secondary to malignant disease

          -  Clinically significant bleeding excluding drainage

          -  Documented congenital or acquired bleeding disorder

          -  Patients, who have contraindications for thromboprophylaxis or contraindications to
             take rivaroxaban according to FDA-approved product label

          -  Patient on oral anticoagulation therapy in the past 7 days

          -  Pregnancy or breastfeeding

          -  Patients who are simultaneously participating in a different study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thanainit Chotanaphut, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Orthopaedic Surgery Pharmongkutklao Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Orthopaedics, Chulalongkorn Hospital</name>
      <address>
        <city>Pathumwan</city>
        <state>Bangkok</state>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aree Tanavalee, MD.</last_name>
      <phone>662-256-4212</phone>
      <email>areetana@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Aree Tanavalee, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Orthopedic Surgery, Police General Hospital</name>
      <address>
        <city>Pathumwan</city>
        <state>Bangkok</state>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thana Turajane, MD.</last_name>
      <phone>662 3193025</phone>
      <email>thanaturajane@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Thana Turajane, MD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Orthopaedic surgery Pharmongkutklao Hospital</name>
      <address>
        <city>Rajathevee</city>
        <state>Bangkok</state>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thanainit Chotanaphut, M.D.</last_name>
      <phone>662 3547600</phone>
      <phone_ext>93504</phone_ext>
      <email>me-pmk@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Thanainit Chotanaphut, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Orthopaedic Surgery,Chiang Mai University</name>
      <address>
        <city>Muang</city>
        <state>Chiang Mai</state>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prasit Wongtriratanachai, MD.</last_name>
      <phone>66-5394-5544</phone>
      <email>prasitjo@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Prasit Wongtriratanachai, MD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Orthopaedics, Thammasat University</name>
      <address>
        <city>Klong Luang</city>
        <state>Pathumthani</state>
        <zip>12121</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Boonchana Pongcharoen, MD.</last_name>
      <phone>662 9269775</phone>
      <email>boonbigbear@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Boonchana Pongcharoen, MD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Orthopedic/Board of Orthopedic Surgery, Saint Louis Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10120</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thanin Santhanavanich, MD.</last_name>
      <phone>662 210 9999</phone>
      <email>thanin@saintlouis.or.th</email>
    </contact>
    <investigator>
      <last_name>Thanin Santhanavanich, MD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Orthopedic Surgery, Bhumibol Adulyadej Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10220</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thana Narinsorasak, MD.</last_name>
      <phone>662 5347000</phone>
      <phone_ext>27365</phone_ext>
    </contact>
    <investigator>
      <last_name>Thana Narinsorasak, MD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2012</study_first_submitted>
  <study_first_submitted_qc>January 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2012</study_first_posted>
  <last_update_submitted>January 11, 2012</last_update_submitted>
  <last_update_submitted_qc>January 11, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Phramongkutklao College of Medicine and Hospital</investigator_affiliation>
    <investigator_full_name>Dr.Thanainit Chotanaphuti</investigator_full_name>
    <investigator_title>Colonel</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
    <mesh_term>Hip Fractures</mesh_term>
    <mesh_term>Fractures, Open</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

